A5100410171- Pharmacogenetics and Drug Metabolism
- Diabetes Treatment and Management
- Gastroesophageal reflux and treatments
- Pharmacological Effects and Toxicity Studies
- Helicobacter pylori-related gastroenterology studies
- Drug Transport and Resistance Mechanisms
- Antibiotics Pharmacokinetics and Efficacy
- Potassium and Related Disorders
- Analytical Methods in Pharmaceuticals
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Statistical Methods in Clinical Trials
- Epilepsy research and treatment
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Drug-Induced Hepatotoxicity and Protection
- Gastrointestinal motility and disorders
- Lipoproteins and Cardiovascular Health
- HIV/AIDS drug development and treatment
- Pharmaceutical Economics and Policy
- Biosimilars and Bioanalytical Methods
- Pharmacology and Obesity Treatment
- Inflammatory mediators and NSAID effects
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
Seoul National University Hospital
2016-2025
Seoul St. Mary's Hospital
2024
Catholic University of Korea
2024
University of Ottawa
2021-2024
New Generation University College
2017-2024
National University College
2017-2024
Seoul National University
2009-2024
Weatherford College
2024
Jeju National University
2024
Engineering Service Center und Handel (Germany)
2023
Introduction Neuropathic pain is a debilitating condition. The importance of neuroimmune interactions in neuropathic has been evidenced by the involvement different immune cells peripheral and central sensitization pathological pain. Macrophages microglia are most abundant activated injured nerves spinal cord, respectively. Several lines evidence showed that macrophage/microglia survival, activation, proliferation, differentiation require macrophage-colony stimulating factor. In this study,...
Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump inhibitors. Tegoprazan, a novel potassium‐competitive blocker, is expected to show improved properties for this need. This study was aimed compare night‐time suppression by tegoprazan with that vonoprazan or esomeprazole, and explore the effect CYP2C19 phenotypes on acid‐suppressive effects. Methods A randomized, open‐label, 3‐period, 6‐sequence crossover conducted. single oral dose 50 mg, 20 mg esomeprazole 40...
The current study assessed the influence of CYP2C19 genotype on pharmacokinetics and tolerability voriconazole after single multiple oral doses in healthy volunteers. Six subjects for homozygous extensive metabolizer (EMs), 6 heterozygous (HEMs), poor (PMs) were enrolled, their CYP2C9, CYP3A5, MDR1 genotypes analyzed. After a intravenous infusion or 200 mg voriconazole, plasma concentrations measured. Bioavailability was not significantly different among genotypes. Voriconazole exposure PMs...
Ursodeoxycholic acid (UDCA) is a metabolic by-product of intestinal bacteria, showing hepatoprotective effects. However, its underlying molecular mechanisms remain unclear. The purpose this study was to elucidate the action protective effects UDCA and vitamin E against liver dysfunction using metabolomics metagenomic analysis. In study, we analysed blood urine samples from patients with obesity dysfunction. Nine were randomly assigned receive (300 mg twice daily), 10 subjects received (400...
Digital therapeutics (DTx) are software-based therapeutic interventions based on clinical evidence. Randomized trials (RCTs) often the source of evidence, similar to conventional drugs or medical devices. However, novel approaches such as use real-world data digital biomarkers also utilized. This article aimed review how DTx products have been clinically evaluated.DTx approved by US Food and Drug Administration 2020 were reviewed with sufficient published information selected. Pivotal...
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Atenolol is an antihypertensive drug, of which negligible amounts are metabolized. Fruit juices may decrease the oral absorption drugs by inhibiting intestinal drug transporters, as demonstrated in vitro and vivo . STUDY ADDS The pharmacokinetic characteristics atenolol were determined according to SLCO2B1 genotype after apple juice administration healthy Korean volunteers. Apple ingestion markedly reduced systemic exposure atenolol, but genetic...
The innovative pure laparoscopic living donor right hepatectomy (LLDRH) procedure for liver transplantation has never been fully compared to open (OLDRH). We aimed compare the safety and graft results of LLDRH those OLDRH.From May 2013 July 2017, 288 consecutive donors underwent either OLDRH (n = 197) or 91). After propensity score matching, 72 were included in each group. primary outcome was postoperative complications during a 90-day follow-up period. Comprehensive complication index,...
Aims Helicobacter pylori (Hp) eradication plays a key role in the treatment and prevention of peptic ulcer diseases. Increasing clarithromycin resistance Hp necessitates more effective treatments for eradication, such as bismuth‐containing quadruple therapy. We aimed to compare safety pharmacokinetics (PK) bismuth between vonoprazan‐ lansoprazole‐containing therapy Hp‐positive subjects. Methods In this randomised, double‐blind, parallel‐group study, subjects were randomised receive or Each...
Although metformin has been reported to affect the gut microbiome, mechanism not fully determined. We explained potential underlying mechanisms of through a multiomics approach.An open-label and single-arm clinical trial involving 20 healthy Korean was conducted. Serum glucose insulin concentrations were measured, stool samples collected analyze microbiome. Untargeted metabolomic profiling plasma, urine, performed by GC-TOF-MS. Network analysis applied infer hypoglycemic effect metformin.The...
Zastaprazan (JP-1366) is a novel potassium-competitive acid blocker with favourable preclinical safety and efficacy profile being developed for the treatment of acid-related diseases.To investigate safety, tolerability, pharmacodynamics pharmacokinetics zastaprazan.A randomised, open-label, placebo- active-controlled, single multiple ascending dose clinical trial was conducted in healthy Korean male subjects. Intragatric pH serum gastrin were measured to assess pharmacodynamics, while serial...
CYP2C19-mediated drug interactions of acid-reducing agents are clinically important given the high possibility concomitant administration with CYP2C19 substrates. This study aimed to evaluate effect tegoprazan on pharmacokinetics (PK) a substrate, proguanil, compared vonoprazan or esomeprazole. A two-part, randomized, open-label, two-sequence, three-period crossover was conducted in 16 healthy extensive metabolizers (eight subjects per part). In each period, single oral dose...
OBJECTIVES: Proguanil, an antimalarial drug, is metabolized into cycloguanil by the cytochrome P450 2C19 (CYP2C19). Interestingly, hepatic uptake via organic transporter 1 (OCT1), encoded polymorphic gene SLC22A1, has been reported to affect biotransformation of proguanil. Building on this, we developed a semi-physiologic population pharmacokinetic (PK) model proguanil and evaluate effect SLC22A1 1022 C>T genetic polymorphism metabolism cycloguanil.METHODS: A PK was based total 160 plasma...
Objectives: DA-8010 is a novel muscarinic receptor 3 (M3) antagonist with extended-release formulation for the treatment of overactive bladder (OAB). The pharmacokinetics present complexity during absorption phase, characterized by multiple "shoulders", which cannot be adequately described conventional first- or zero-order models. objective this study was to develop population pharmacokinetic (PK) model capable characterizing PK profile DA-8010, incorporating various models.Methods: A total...
Despite interest in clinical trials with decentralized elements (DCTs), analysis of their trends trial registries is lacking due to heterogeneous designs and unstandardized terms. We explored Llama 3, an open-source large language model, efficiently evaluate these trends. Trial data were sourced from Aggregate Analysis ClinicalTrials.gov, focusing on drug conducted between 2018 2023. utilized three 3 models a different number parameters: 8b (model 1), fine-tuned 2) curated data, 70b 3)....
Oro-facial pain following injury and infection is frequently observed in dental clinics. While neuropathic evoked by associated with nerve lesion has an involvement of glia/immune cells, inflammatory hyperalgesia exaggerated sensitization mediated local circulating immune mediators. To better understand the contribution central nervous system (CNS) glial cells these different pathological conditions, this study we sought to characterize functional phenotypes response trigeminal (loose...
Summary Background Potassium‐competitive acid blockers (P‐CABs) are emerging as novel treatments for acid‐related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan approved P‐CABs in South Korea, but the pharmacodynamics safety/tolerability of two drugs have never been compared. Aims To evaluate tegoprazan after single multiple oral doses Methods A randomised, open‐label, active‐controlled study was conducted Helicobacter pylori ‐negative healthy Korean male...
There are several hurdles to overcome before implementing pharmacogenomics (PGx) in precision medicine.One of the is unawareness PGx by clinicians due insufficient pharmacogenomic information on drug labels.Therefore, it might be important implement that reflects labels, standard prescription for clinicians.This study aimed evaluate level at which was being used clinical practice comparing Clinical Pharmacogenetics Implementation Consortium and Dutch Working Group guidelines labels US Food...
Summary Background DWP14012 (fexuprazan), a novel potassium‐competitive acid blocker, is under development for the treatment of acid‐related disorders. Aims To compare pharmacodynamics (PDs), pharmacokinetics (PKs) and safety among healthy subjects Korean, Caucasian Japanese descent. Methods A randomised, double‐blind, placebo‐controlled, single‐ multiple‐dose study was conducted. Ten in each dose group (40, 60 or 80 mg Koreans; 40 Caucasians; 20, Japanese) were randomly assigned to placebo....
DWP16001 is a novel sodium-glucose cotransporter-2 inhibitor under development for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate pharmacokinetics, pharmacodynamics and safety after single multiple doses in healthy subjects.A randomized, double-blind, placebo- active-controlled, single- multiple-dose conducted. Twelve subjects each dose group received (0.2, 0.5, 1.0, 2.0 or 5.0 mg) (0.1, 0.3, 1.0 mg once daily 15 consecutive days) DWP16001, dapagliflozin 10...